Circulating malondialdehyde-modified low-density lipoprotein (MDA-LDL), which is a type of oxidized LDL with malondialdehyde-modified (MDA) adduction onto apolipoprotein B, has been well-known to be linked to atherosclerosis in patients of CAD [11,12], as well as being shown to be a useful predictor for major CV events or vulnerable coronary arterial plaque for CAD in DM patients [13,14,15]. Here, APOB is linked to coronary artery disorder.